Author + information
- Received May 27, 2009
- Revision received August 21, 2009
- Accepted September 17, 2009
- Published online February 1, 2010.
- Jonathan R. Lindner, MD⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Jonathan R. Lindner, Cardiovascular Division UHN-62, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239
Methods for noninvasive imaging of specific disease-related molecular changes are being developed in order to expand and improve diagnostic capabilities and to enhance therapeutic decision making in the clinical setting. These new techniques have also started to be incorporated into research programs in order to better characterize pathophysiology or evaluate treatment efficacy. Molecular imaging with contrast-enhanced ultrasound relies on the detection of the acoustic signal produced by either microbubbles or other acoustically active particulate agents that are targeted to sites of disease. This review describes the progress that has been made in the development and testing of methods for contrast ultrasound molecular imaging of cardiovascular disease. Specifically, topics that will be addressed include: 1) the bioengineering and detection schemes for targeted probes; 2) specific disease processes (myocardial ischemia, atherosclerosis, and transplant rejection) where molecular imaging may play a role; and 3) the potential role of ultrasound as a molecular imaging technique.
Sanjiv Kaul, MD, served as Guest Editor for this article.
- Received May 27, 2009.
- Revision received August 21, 2009.
- Accepted September 17, 2009.
- American College of Cardiology Foundation
- Overview of Molecular Imaging
- Bioengineering of Targeted Ultrasound Contrast Probes
- Detection of Infarction and Acute Ischemia
- Early Detection of Atherosclerosis
- Heart Transplant Rejection
- Imaging Vascular Adaptation to Ischemia
- Advantages and Limitations to the Technique